Company Overview
Company Type: Public Company
Website: www.auriniapharma.com
Number of Employees: 300
Ticker: AUPH (NasdaqGM)
Year Founded: 1993


Business Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
220.0
Market Capitalization
1,416.6
TEV/Total Revenue
4.9x
EBITDA
(111.9)
Total Enterprise Value
1,074.3
TEV/EBITDA
NM
EBIT
(115.5)
Cash & ST Invst.
481.4
P/Diluted EPS Before Extra
NM
Net Income
(99.9)
Total Debt
139.0
Price/Tang BV
2.7x
Capital Expenditure
(1.0)
Total Assets
754.1
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS (GAAP)
(0.23)
-
(0.79)
-
(0.65)
Revenue (mm)
52.90
-
222.07
164.85 - 192.33
248.94
EBITDA (mm)
(21.16)
-
(100.08)
-
(73.15)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
4.84x
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Outperform (1.88)
Target Price
19.23
Potential Upside
94.71%


Key Professionals
Name
Title
Greenleaf, Peter S.
President, CEO & Director
Miller, Joseph M.
Chief Financial Officer
Donley, Matthew Maxwell
Executive Vice President of Operations & Strategy
Harrell, James Archie
Head of Investor Relations
Robertson, Stephen P.
Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer
Lynch, Fran 
Vice President of Sales
Evans, Sue 
Senior Vice President of Global Regulatory Affairs
Habig, Scott 
Chief Commercial Officer
Knappertz, Volker 
Executive Vice President of Research & Development
Martin, Michael R.
Chief Business Officer
Sheel, DeDe 
Vice President of Investor Relation

Key Board Members
Name
Title
Billen, Daniel G.
Chairman
Greenleaf, Peter S.
President, CEO & Director
Leversage, Jill Diane
Independent Director
Mackay-Dunn, R. Hector
Independent Director
Bailey, Jeffrey Allen
Director
Balakrishnan, Brinda 
Independent Director
Foster, Robert T.
Director
Jayne, David R. W.
Independent Non-Executive Director
Smith, Karen L.
Director


Primary Industry Classification
Biotechnology


Primary Office Location
4464 Markham Street Suite 1203 | Victoria, BC | V8Z 7X8 | Canada
Phone: 250 708 4272   

Current and Pending Investors
3SBio Inc. (SEHK:1530) (Pending), Abingworth LLP, Apple Tree Partners, Great Point Partners, LLC, HealthCor Management L.P., ILJIN Life Science Co., Ltd., ILJIN Semiconductor Co., Ltd., ILJIN SNT Co., Ltd, KB Investment Co., Ltd., Lumira Ventures (Benjamin Rovinski, Peter van der Velden, Richard Glickman), MKT Capital Ltd, New Enterprise Associates, Inc., Paladin Labs Inc., RA Capital Management, L.P., Redmile Group, LLC, SBI Investment KOREA Co., Ltd. (KOSDAQ:A019550), venBio LLC, Vivo Capital, LLC

Prior Investors
Difference Capital Financial Inc., HBM Partners Ltd., JP SPC 5 - Market Tactical Fund Segregated Portfolio, Roche Venture Fund, Roche Venture Fund

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 10.06
Market Cap (mm)
1,416.6
Open
 9.90
Shares Out. (mm)
143.4
Previous Close
 9.88
Float %
98.0%
Change on Day
0.18
Shares Sold Short (mm)
17.0
Change % on Day
1.8%
Dividend Yield %
-
Day High/Low
 10.19/ 9.59
Diluted EPS Excl. Extra Items
(0.70)
52 wk High/Low
 17.08/ 5.59
P/Diluted EPS Before Extra
NM
Volume (mm)
1.45
Avg 3M Dly Vlm (mm)
2.14
Beta 5Y
1.23


 
Delayed Quote** | Last Updated on Oct-05-2023 03:22 PM (GMT-5)
NasdaqGM:AUPH - Common Stock


Index Membership
S&P Americas Under USD3 Billion Index;S&P Americas BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Under USD2 Billion Index;S&P Americas BMI Growth Index;S&P Americas SmallCap Health Care (Sector) Index;S&P Canada SmallCap Index;S&P Canada SmallCap Growth Index;S&P Canada SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas SmallCap Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Between USD500 Million and USD2.5 Billion Index;S&P Canada BMI Growth Index;S&P Americas SmallCap Growth Index;S&P Americas Under USD1.5 Billion Index;S&P Canada Under USD2 Billion Index;S&P Americas Between USD1 Billion and USD5 Billion Index;S&P Americas SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia Between USD1 Billion and USD5 Billion Index;S&P DM Ex-Australia SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada SmallCap Health Care (Sector) Index;S&P Canada Under USD3 Billion Index;S&P Canada BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Europe Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Europe BMI Growth Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Health Care (Sector) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed Ex-Eurozone SmallCap Index;S&P Developed Ex-Eurozone SmallCap Health Care (Sector) Index;S&P Developed Between USD1 Billion and USD5 Billion Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia Under USD3 Billion Index;S&P Developed Ex-Europe BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Growth Index;S&P Developed Ex-Switzerland Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland SmallCap Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Switzerland Under USD3 Billion Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone Under USD1.5 Billion Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Under USD2 Billion Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan Under USD2 Billion Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland Under USD2 Billion Index;S&P Developed Ex-Europe SmallCap Index;S&P Developed Ex-Europe Under USD1.5 Billion Index;S&P Developed Ex-Eurozone Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific Under USD3 Billion Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Growth Index;S&P DM Ex-U.S. & Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.K. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Index;S&P Developed Ex-U.S. & Japan SmallCap Health Care (Sector) Index;S&P Developed Ex-Europe Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD3 Billion Index;S&P Developed Ex-U.S. & Japan Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan Under USD2 Billion Index;S&P Developed Ex-U.S. & U.K. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Index;S&P Developed Ex-U.S. & U.K. BMI Growth Index;S&P Developed Ex-U.S. & U.K. SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. Under USD3 Billion Index;S&P Developed Ex-U.S. BMI Growth Health Care (Sector) Index;S&P Developed Under USD3 Billion Index;S&P Developed Ex-U.S. SmallCap Health Care (Sector) Index;S&P Developed SmallCap Index;S&P Developed Ex-Eurozone SmallCap Growth Index;S&P DM Ex-Eurozone SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Health Care (Sector) Index;S&P DM Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada Between USD500 Million and USD2.5 Billion Index;S&P Canada BMI Growth Health Care (Sector) Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. SmallCap Index;S&P Developed Ex-U.K. Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. & Japan BMI Index;S&P Developed Ex-U.S. & Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Growth Index;S&P Developed Ex-U.K. SmallCap Health Care (Sector) Index;S&P Developed Between USD500 Million and USD2.5 Billion Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Under USD2 Billion Index;S&P Developed Ex-Eurozone Under USD3 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Index;S&P Developed Ex-U.S. & U.K. Under USD1.5 Billion Index;S&P Developed Ex-U.S. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.S. BMI Growth Index;S&P Developed Ex-U.S. & U.K. Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Growth Health Care (Sector) Index;S&P DM Ex-U.S. & U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & U.K. SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. Under USD2 Billion Index;S&P Developed Ex-U.S. BMI Index;S&P Developed Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Growth Index;S&P Global Between USD1 Billion and USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe Under USD2 Billion Index;S&P Developed Ex-Europe Under USD3 Billion Index;S&P Developed Ex-Japan SmallCap Index;S&P Developed Ex-Switzerland Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD1.5 Billion Index;S&P Developed Under USD1.5 Billion Index;S&P Developed Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Japan Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Japan SmallCap Growth Index;S&P Developed Ex-Switzerland SmallCap Index;S&P Developed Ex-Switzerland SmallCap Growth Index;S&P Developed Ex-Switzerland Under USD1.5 Billion Index;S&P Developed Ex-U.K. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. Under USD2 Billion Index;S&P Developed Ex-U.K. Under USD3 Billion Index;S&P Canada Between USD1 Billion and USD5 Billion Index;S&P Canada BMI Index;S&P Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan SmallCap Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Asia-Pacific SmallCap Index;S&P Developed Ex-U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Global Ex-Japan Under USD1.5 Billion Index;S&P Global Ex-Japan Under USD2 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Growth Index;S&P Developed Ex-Japan Under USD3 Billion Index;S&P Developed Ex-U.K. Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-U.K. BMI Index;S&P Global Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Japan Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Japan Between USD500 Million and USD2.5 Billion Index;S&P Global BMI Index;S&P Global Ex-Japan Under USD3 Billion Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-Pan Asia SmallCap Growth Index;S&P Global Ex-U.S. SmallCap Growth Index;S&P Global SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Index;S&P Developed Ex-U.S. Under USD2 Billion Index;S&P Developed Under USD2 Billion Index;S&P Global Ex-U.S. SmallCap Health Care (Sector) Index;S&P Global Ex-U.S. Under USD3 Billion Index;S&P Global Under USD2 Billion Index;S&P Global Under USD3 Billion Index;S&P Global SmallCap Index;S&P Global SmallCap Growth Index;S&P North America SmallCap Index;S&P North America SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Index;S&P Global Ex-Pan Asia SmallCap Health Care (Sector) Index;S&P Global Ex-Pan Asia Under USD1.5 Billion Index;S&P Global Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. SmallCap Index;S&P Global Ex-U.S. Under USD2 Billion Index;S&P North America BMI Index;S&P Global SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia Between USD1 Billion and USD5 Billion Index;S&P Global Ex-Pan Asia Under USD2 Billion Index;S&P Global Ex-Pan Asia Under USD3 Billion Index;S&P Global Ex-U.S. Between USD500 Million and USD2.5 Billion Index;S&P Global Ex-U.S. BMI Index;S&P Global Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. Under USD1.5 Billion Index;S&P Global Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan Under USD3 Billion Index;S&P North America SmallCap Growth Health Care (Sector) Index;S&P North America BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America SmallCap Health Care (Sector) Index;S&P North America Under USD1.5 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America Under USD2 Billion Index;S&P North America Under USD3 Billion Index;S&P Global BMI Growth Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P North America BMI Growth Index;S&P North America BMI Growth Health Care (Sector) Index;S&P North America BMI Health Care (Sector) Index;S&P Canada SmallCap Growth Health Care (Sector) Index;S&P Canada Under USD1.5 Billion Index;S&P Developed Ex-Asia-Pacific Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Under USD1.5 Billion Index;S&P Developed Ex-Australia Under USD1.5 Billion Index;S&P Developed Ex-Australia Under USD2 Billion Index;S&P DM Ex-Europe SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-Japan Under USD1.5 Billion Index;S&P Developed Ex-U.K. SmallCap Growth Index;S&P Developed Ex-U.S. & Japan Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed SmallCap Growth Index;S&P Developed SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-Japan SmallCap Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia SmallCap Index;S&P Global Ex-U.S. Between USD1 Billion and USD5 Billion Index;S&P North America Between USD1 Billion and USD5 Billion Index;S&P North America Between USD500 Million and USD2.5 Billion Index;S&P North America SmallCap Growth Index;S&P Developed Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & Japan BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel SmallCap Growth Index;S&P Developed Ex-Israel SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Index;S&P Developed Ex-Israel SmallCap Health Care (Sector) Index;S&P DM Ex-Israel SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel BMI Between USD1 Billion and USD5 Billion Index;S&P Developed Ex-Israel BMI Between USD500 Million and USD2.5 Billion Index;S&P Developed Ex-Israel Under USD1.5 Billion Index;S&P Developed Ex-Israel Under USD2 Billion Index;S&P Developed Ex-Israel Under USD3 Billion Index;S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P Americas Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Canada Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Asia-Pacific Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Australia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Europe Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Eurozone Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Israel Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-Switzerland Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.K. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. & Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. & U.K. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed Ex-U.S. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Japan Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-Pan Asia Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Global Ex-U.S. Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P North America Cap Range Companies Between USD500 Million and USD5 Billion Index;S&P Developed BMI Ex-U.S. & Korea Index;S&P DM Ex. Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Australia SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P DM Ex-Israel SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed Ex-U.S. & Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P Developed Ex-U.S. & U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Canada SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia-Pacific SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P DM Ex-Europe SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Eurozone SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.S. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia & New Zealand Between USD1 Billion and USD5 Billion;S&P Global Ex-China A BMI;S&P Global Ex-China A SmallCap;S&P Global Ex-U.S. & China A BMI;S&P Global Ex-U.S. & China A SmallCap;S&P Developed Ex-Korea BMI;S&P Developed Ex-U.S. & Korea SmallCap;S&P Developed Ex-Korea SmallCap;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. SmallCap Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Thunderbolt Pharma, Inc.
Thunderbolt Pharma, Inc. develop BAFF/APRIL dual antagonists for B cell disorders. The company was incorporated in 2016 and is based in South San Francisco, California. Thunderbolt Pharma, Inc. operates as a subsidiary of Aurinia Pharmaceuticals Inc.

United States and Canada
Biotechnology
-
-
-
Aurinia Pharmaceuticals Inc. Prior To Merger With Isotechnika Pharma Inc.
As of September 23, 2013, Aurinia Pharmaceuticals Inc. was acquired by Isotechnika Pharma Inc. Aurinia Pharmaceuticals Inc. operates a clinical stage pharmaceutical company which focuses on the global nephrology market. The company holds the license for voclosporin in lupus nephritis. Aurinia Pharmaceuticals Inc. is based in Victoria, Canada.

United States and Canada
Pharmaceuticals
-
-
-
Aurinia Pharma Limited
Aurinia Pharma Limited is a research and consulting services company. It was incorporated in 2006 and is headquartered in London, United Kingdom.

Europe
Research and Consulting Services
-
-
-
Aurinia Pharma U.S., Inc.
Aurinia Pharma U.S., Inc. is a pharmaceuticals company. It is based in Rockville, Maryland.

United States and Canada
-
5.00
-
-
Isodiagnostika Inc

-
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-26-2023
-
Shelf Registration
Target
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)


15.21
Nov-19-2021
-
Shelf Registration
Target
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)


250.00
Aug-17-2021
Aug-17-2021
Merger/Acquisition
Buyer
Thunderbolt Pharma, Inc.
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)

0.75
Jun-25-2021
-
Shelf Registration
Target
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)


158.92
Feb-24-2021
-
Shelf Registration
Target
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)


65.33
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-21-2023
Executive/Board Changes - Other
Aurinia Pharmaceuticals Appoints Robert T. Foster to its Board
Aug-21-2023
Executive/Board Changes - Other
Aurinia Pharmaceuticals Inc. Announces Board Changes
Aug-03-2023
Corporate Guidance - New/Confirmed
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2023
Aug-03-2023
Earnings Calls
Aurinia Pharmaceuticals Inc., Q2 2023 Earnings Call, Aug 03, 2023
Jul-19-2023
Product-Related Announcements
Aurinia Pharmaceuticals Inc. Announces Full Results from the Phase 3, Double-Blind, Placebo-Controlled Aurora 2 Extension Study

Competitors
AstraZeneca PLC (LSE:AZN), ChemoCentryx, Inc., GSK plc (LSE:GSK)

M&A Advisors
Borden Ladner Gervais LLP


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Borden Ladner Gervais LLP
Private Placement Advisors
B. Riley Securities, Inc., Banc of America Securities LLC, Borden Ladner Gervais LLP, Canaccord Genuity Corp., Canaccord Genuity Group Inc. (TSX:CF), Canaccord Genuity LLC, Deloitte & Touche Corporate Finance Canada Inc., Leerink Partners LLC
Public Offering Advisors
Borden Ladner Gervais LLP, Bryan & Company LLP, Cooley LLP, PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Canada
Key development Advisor
B. Riley Securities, Inc., Deloitte & Touch (Middle East) Jordan, Lazard Ltd (NYSE:LAZ), Leerink Partners LLC, RF Securities Clearing LP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:19 AM
AUPH
Aurinia Pharmaceuticals Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 02:49 AM
AUPH
ValuEngine Rating and Forecast Report for AUPH
Reports
11
The Economy Matters

Oct 02, 2023 01:51 AM
AUPH
The Economy Matters
Reports
8
CFRA Equity Research

Oct 01, 2023 10:01 AM
AUPH
Aurinia Pharmaceuticals Inc.
Reports
9
H.C. Wainwright & Co.
Arce, Antonio Eduardo
Sep 22, 2023 04:07 AM
AUPH
Dr. Robert Foster Joins Aurinia's Board As Part of Cooperation Agreement Between Aurinia and MKT Capital; Affirm Buy
Reports
3
Valuation & Research Specialists
VRS Research Team
Sep 17, 2023 04:51 PM
AUPH
AURINIA PHARMACEUTICALS INC. Flash Note
EPS Estimates*
15
GlobalData

Sep 15, 2023 03:25 AM
AUPH
Aurinia Pharmaceuticals Inc (AUPH.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
136
MarketLine

Sep 14, 2023 06:01 AM
AUPH
Aurinia Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
67
GlobalData

Sep 13, 2023 04:06 AM
AUPH
Aurinia Pharmaceuticals Inc (AUPH.NASD) - Financial Analysis Review
Reports
359
Marktfeld
Paraskevopoulos, Michail
Sep 10, 2023 01:02 PM
AUPH
Aurinia Pharmaceuticals Inc (AUPH.US): Investor Targeting - September 2023
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


BlackRock, Inc.

8,333,034

5.81

83.5

Jun-30-2023


ILJIN SNT Co., Ltd

6,060,290

4.23

60.8

May-10-2023


Armistice Capital LLC

4,692,000

3.27

47.0

Jun-30-2023


New Enterprise Associates, Inc.

3,969,834

2.77

39.8

Jun-30-2023


State Street Global Advisors, Inc.

2,632,486

1.84

26.4

Jun-30-2023


Teachers Insurance and Annuity Association-College Retirement Equities Fund

2,578,712

1.80

25.9

Aug-31-2023


Morgan Stanley, Investment Banking and Brokerage Investments

1,590,036

1.11

15.9

Jun-30-2023


Goldman Sachs Asset Management, L.P.

1,577,021

1.10

15.8

Jun-30-2023


Renaissance Technologies LLC

1,530,400

1.07

15.3

Jun-30-2023


Geode Capital Management, LLC

1,410,766

0.98

14.1

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Goldman Sachs Asset Management, L.P.
1,577,021
711,140
Two Sigma Investments, LP
1,368,171
644,569
TIG Advisors, LLC
561,096
561,096
J. Goldman & Co., L.P.
552,407
552,407
Armistice Capital LLC
4,692,000
520,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Citadel Advisors LLC
361,998
(2,085,275)
Point72 Asset Management, L.P.
569,758
(1,641,239)
Natixis, Investment Banking and Corporate Banking Investments
262,256
(963,231)
Balyasny Asset Management L.P.
805,534
(506,813)
Woodline Partners LP
500,000
(453,462)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
AUR200 (Future), AUR300 (Future), Isomax, Licensing of LUPKYNIS, LUPKYNIS, LUVENIQ (Future), TAFA93 (Future), TKB662 (Future), Voclera (Future)


Upcoming Events
Date/Time
Type
Nov-03-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-21-2023
Sep-21-2023
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEC
8-K (1.01, 5.02, 7.01, 9.01)
341 KB
Sep-21-2023
-
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEDAR
News Releases
84 KB
Sep-21-2023
-
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEDAR
News Releases
424 KB
Sep-21-2023
-
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEDAR
News Releases
285 KB
Aug-21-2023
Aug-18-2023
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEC
8-K (5.02, 9.01)
188 KB
Aug-21-2023
-
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEDAR
News Releases
108 KB
Aug-03-2023
Jun-30-2023
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEDAR
Interim Financial Statements
680 KB
Aug-03-2023
-
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEDAR
News Releases
85 KB
Aug-03-2023
-
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEDAR
News Releases
186 KB
Aug-03-2023
Jun-30-2023
Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH)
SEC
10-Q
6 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D., Robert T. (Director)
Sep-21-2023
Common Shares
(6,335,710)
-
Other Disposition
(100.00)
Multiple
-
Sep-21-2023
Common Shares
(2,006,820)
-
Other Disposition
-
Exchange Announcement
-
Sep-21-2023
Common Shares
(4,328,890)
-
Other Disposition
-
Exchange Announcement
Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C., R. Hector (Independent Director)
May-23-2023
Common Shares
(4,818)
(74,527)
Open Market Disposition
(24.42)
Form 4
Leversage C.A., F.C.A., Jill Diane (Independent Director)
May-23-2023
Common Shares
(4,815)
(74,480)
Open Market Disposition
(34.31)
Form 4
Billen M.D., Ph.D., Daniel G. (Chairman)
May-23-2023
Common Shares
(4,650)
(71,928)
Open Market Disposition
(12.22)
Form 4
Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C., R. Hector (Independent Director)
May-22-2023
Common Shares
(4,818)
(74,465)
Private Disposition
(24.42)
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Billen, Daniel G.
Chairman
250 708 4272
-

Greenleaf, Peter S.
President, CEO & Director
250 708 4272
-

Leversage, Jill Diane
Independent Director
250 708 4272
-

Mackay-Dunn, R. Hector
Independent Director
(604) 661-9307
(604) 661-9349
hmackay-dunn@farris.com
Bailey, Jeffrey Allen
Director
250 708 4272
-

Balakrishnan, Brinda 
Independent Director
250 708 4272
-

Foster, Robert T.
Director
250 708 4272
(780) 484-4105
rfoster@contravir.com
Jayne, David R. W.
Independent Non-Executive Director
250 708 4272
-

Smith, Karen L.
Director
250 708 4272
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Greenleaf, Peter S.
President, CEO & Director
250 708 4272
-

Miller, Joseph M.
Chief Financial Officer
250 708 4272
-
jmiller@cerecor.com
Donley, Matthew Maxwell
Executive Vice President of Operations & Strategy
250 708 4272
-

Harrell, James Archie
Head of Investor Relations
250 708 4272
-

Robertson, Stephen P.
Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer
250 708 4272
-

Lynch, Fran 
Vice President of Sales
250 708 4272
-
-
Evans, Sue 
Senior Vice President of Global Regulatory Affairs
250 708 4272
-

Habig, Scott 
Chief Commercial Officer
250 708 4272
-

Knappertz, Volker 
Executive Vice President of Research & Development
250 708 4272
-

Martin, Michael R.
Chief Business Officer
250 708 4272
-
mmartin@auriniapharma.com
Sheel, DeDe 
Vice President of Investor Relation
250 708 4272
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
